Therapeutic efficacy of platelet transfusion treated with amotosalen/UVA pathogen inactivation technology (INTERCEPT
Journal
Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
16
06
2022
accepted:
25
11
2022
medline:
13
9
2023
pubmed:
17
2
2023
entrez:
16
2
2023
Statut:
ppublish
Résumé
The INTERCEPT After comparing the transfusion efficiency between pathogen-reduced platelets (PR_PLT) and untreated platelet products (U_PLT), our single-center observational study assessed the effectiveness of PR_PLT for the prevention of bleeding and for therapeutic treatment of WHO grade 2 bleeding in 176 patients undergoing chemotherapy with curative intent for acute myeloid leukemia (AML). The main endpoints were the 24-hour (h) corrected count increment (24h_CCI) after each transfusion, and time to next transfusion. Whereas the transfused doses tended to be higher in the PR_PLT group compared to U_PLT, there was a significant difference in intertransfusion interval (ITI) and 24h_CCI. In prophylactic transfusions, PR_PLT transfusions of >0.65×10 These results, which must be confirmed by prospective studies, indicate the need for vigilance regarding the quantity and quality of PR_PLT products used to treat patients at risk of bleeding crisis. Future prospective studies are needed to confirm these findings.
Sections du résumé
BACKGROUND
The INTERCEPT
MATERIALS AND METHODS
After comparing the transfusion efficiency between pathogen-reduced platelets (PR_PLT) and untreated platelet products (U_PLT), our single-center observational study assessed the effectiveness of PR_PLT for the prevention of bleeding and for therapeutic treatment of WHO grade 2 bleeding in 176 patients undergoing chemotherapy with curative intent for acute myeloid leukemia (AML). The main endpoints were the 24-hour (h) corrected count increment (24h_CCI) after each transfusion, and time to next transfusion.
RESULTS
Whereas the transfused doses tended to be higher in the PR_PLT group compared to U_PLT, there was a significant difference in intertransfusion interval (ITI) and 24h_CCI. In prophylactic transfusions, PR_PLT transfusions of >0.65×10
DISCUSSION
These results, which must be confirmed by prospective studies, indicate the need for vigilance regarding the quantity and quality of PR_PLT products used to treat patients at risk of bleeding crisis. Future prospective studies are needed to confirm these findings.
Identifiants
pubmed: 36795348
pii: 2023.0143-22
doi: 10.2450/2023.0143-22
pmc: PMC10497385
doi:
Substances chimiques
amotosalen
K1LDZ0VBC0
Nonoxynol
26027-38-3
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
400-408Références
Proteomics Clin Appl. 2016 Aug;10(8):839-50
pubmed: 27226085
Cochrane Database Syst Rev. 2017 Jul 30;7:CD009072
pubmed: 28756627
Transfusion. 2021 Mar;61(3):919-930
pubmed: 33527430
Vox Sang. 2015 Nov;109(4):343-52
pubmed: 25981525
Ther Adv Hematol. 2020 Mar 18;11:2040620720913010
pubmed: 32215195
Blood Transfus. 2015 Apr;13(2):221-6
pubmed: 25369586
Transfusion. 2020 Sep;60(9):2058-2066
pubmed: 32619068
Transfusion. 2006 May;46(5):731-40
pubmed: 16686840
J Vis Exp. 2012 Dec 07;(70):e4414
pubmed: 23242463
Br J Haematol. 2011 May;153(3):393-401
pubmed: 21418180
Vox Sang. 2012 Aug;103(2):159-76
pubmed: 22519879
Transfusion. 2020 Jun;60(6):1267-1277
pubmed: 32324294
Clin Lab. 2011;57(7-8):451-4
pubmed: 21888008
Transfusion. 2018 Jan;58(1):121-131
pubmed: 29090466
Blood. 2004 Sep 1;104(5):1534-41
pubmed: 15138160
JAMA Oncol. 2018 Apr 01;4(4):468-475
pubmed: 29392283
Blood Rev. 2014 Nov;28(6):235-41
pubmed: 25192602
Transfusion. 2005 Aug;45(8):1335-41
pubmed: 16078923
Ann Hematol. 2020 Apr;99(4):773-780
pubmed: 32088745